Last edition
News about "Glenmark Pharma favipiravir"
Glenmark Pharma releases interim data from PMS study on favipiravir
Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, announced interim data of 503 patients from its post marketing surveillance (PMS) study on favipiravir in India. The PMS study commenced in July 2020 aimed to evaluate safety and efficacy of favipiravir in mild to moderate Covid-19 patients
Glenmark Pharma Favipiravir | 09/06/2021 | By Darshana | 415
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members